Home » Newsletters » BioWorld Science

BioWorld Science

April 6, 2018

View Archived Issues

Acrizanib shows efficacy as topical ocular therapy in models of choroidal neovascularization

Patient enrollment ongoing in phase I trial of HA-1 T TCR T-cell Immunotherapy

Samsung Bioepis initiates phase III trial of proposed ranibizumab biosimilar, SB-11

ST-002 is granted FDA orphan drug designation

Terns Pharmaceuticals acquires three therapeutic candidates for the treatment of NASH from Lilly

AmnioStem cells show superior immune modulatory ability compared to other stem cell types

MCM7 found as a useful marker for intestinal NET grading

Tie1 is a biomarker of survival in patients with metastatic breast cancer

Karo Pharma resolves rights issue regarding acquisition of product portfolio from LEO Pharma

Ubiquigent, FORMA Therapeutics enter DUB enzyme inhibitor collaboration

Biogen and Samsung Bioepis cleared to commercialize Imraldi following AbbVie settlement

Sorrento Therapeutics and Celularity start screening for CD38 CAR-T therapy phase I trial

Ferring Pharmaceuticals to acquire Rebiotix

Strategic collaboration agreement between Nektar and Bristol-Myers Squibb becomes effective

Takeda and DNDi collaborate to develop potential novel drug for visceral leishmaniasis

Injectable hydrogel releases corticosteroid in response to arthritis flares

First cohort dosed in phase I clinical study of PB-2452

Vaccibody initiates first-in-human trial of neoantigen cancer vaccine

SOX-9 successfully distinguishes hepatocellular carcinoma from cholangiocarcinoma

Biopharma Works patents novel serine racemase inhibitors

Menin/MLL interaction inhibitors disclosed by Vitae Pharmaceuticals

Arbutus Biopharma identifies new HBV capsid inhibitors

Aurigene Discovery Technologies divulges new PD-1 inhibitors

Genoscience Pharma initiates first-in-human study of GNS-561 in advanced hepatocellular carcinoma

Decreased OXTR gene methylation tied to schizophrenia

European Commission grants marketing authorization to Lamzede

New phase IIb study explores use of sepranolone for premenstrual dysphoric disorder

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...